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Hyperuricemia is known to be associated with the presence of cardiovascular 
and metabolic syndrome and with the development of incipient kidney disease 
and an accelerated renal progression. However, an elevated uric acid level was 
not generally regarded as a true etiology or mediator, but an indicator of these 
diseases. Uric acid has recently regained the clinical interest and popularity 
based on emerging data suggesting the causative role of hyperuricemia in car-
diovascular and renal disease. Experimental data demonstrates oxidative stress 
is one of the earliest phenomena observed in vascular, renal, liver cells and 
adipocytes exposed to uric acid. Since uric acid is one of the major antioxidants 
of plasma acting as a free radical scavenger and a chelator of transitional metal 
ion, uric acid-induced oxidative stress seems paradoxical. Data regarding the 
clinical implication of hyperuricemia is even more confusing, which defines hy-
peruricemia as a useless parameter to be eliminated from routine follow-up or 
a major risk factor to be therapeutic target. With a review of experimental and 
epidemiologic data, the presence of molecular switch to regulate the role of 
uric acid as anti- or pro-oxidant in different compartment of our body is sug-
gested, which may shed light on understanding the paradoxical role of uric acid 
and solving the “uric acid debate”.
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Introduction
An association of elevated serum uric acid with hyper-
tension, cardiovascular, renal and metabolic disease has 
been reported throughout the 20th century after the first 
description regarding high prevalence of hypertension in 
gout patients in the 1870’s1). A recent meta-analysis re-
veals that a 1 mg/dL increase in serum uric acid level is 
associated with a significant increase of incident hyper-
tension (relative risk 1.13, 95% confidence interval 1.06 
to 1.20) after adjusting for confounding risk factors2). 
Indeed, an elevated serum uric acid is currently the most 
reliable predictor for the development of hypertension. 
There is also a solid data supporting the role of serum 
uric acid as a determinant of the change in estimated 
glomerular filtration rate in diverse spectrum of pop-
ulation from healthy participants with normal kidney 
function to normoalbuminuric diabetics3-8). Higher uric 
acid levels were associated with subsequent worsening of 
kidney function after adjustment for theorized confounders 
such as body mass index, blood pressure and urine albu-
min-creatinine ratio6,7,9). Many epidemiologic studies de- 
monstrated uric acid level as a major predictor for the 
development of incident kidney disease3-8).
Since a simple association based on epidemiologic or 
observational studies did not support the role of hyper-
uricemia as a predictor or causative factor in the develop-
ment of cardiovascular and renal disease, the “uric acid 
debate” has been going on for decades. This debate is 
generated by two major concerns, an absence of random-
ized controlled study using uric acid-lowering therapy in 
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Fig. 1. Production & Metabolism of Uric Acid. XO; xanthine oxi-
dase, XDH; xanthine dehydrogenase, NAD; nicotinamice-adenine
dinucleotide, O2; superoxide.
a large population and a lack of mechanisms by which 
uric acid imposes a detrimental effect on individual organ 
system. Randomized controlled studies to examine the 
etiologic role of hyperuricemia on the progression of car-
diovascular, renal and metabolic diseases are now on-going 
or recruiting the participants, which will provide the an-
swer to clinical implication of hyperuricemia in near future.
In this review, potential mechanism of uric acid-related 
complications in cardiovascular, renal and metabolic dis-
eases will be discussed with a special emphasis on uric 
acid-induced oxidative stress. According to a hypothesis 
by Ames et al, the silencing of uricase gene with an in-
crease in serum uric acid level in humans provided an 
evolutionary advantage for our ancestors10). This hypoth-
esis is based on the results ofin-vitro experiment demon-
strating uric acid as a powerful scavenger of free radical. 
On the other hand, many epidemiologic studies clearly 
show an association of hyperuricemia and clinical con-
ditions described above. The dual role of uric acid as 
an anti-oxidant and pro-oxidant which can be determined 
by specific factors and the interrelation among factors, 
may explain the controversy regarding the role of uric 
acid, however there is no clear explanation for this uric 
acid paradox.
What makesserum uric acid elevated ?
Uric acid is produced from metabolic conversion of 
either dietary or endogenous purines, primarily in the 
liver, muscle, and intestine. The immediate precursor of 
uric acid is xanthine, which is degraded into uric acid by 
xanthine oxidoreductase. Xanthine oxidoreductase may 
attain two inter-convertible forms, xanthine dehydrogen-
ase or xanthine oxidase11). Most xanthine oxidoreductase 
is in the xanthine dehydrogenase form in vivo, which 
is transformed into xanthine oxidase by irreversible pro-
teolytic cleavage or reversible oxidation in specific envi-
ronment including hypoxia12). Xanthine oxidase uses mo-
lecular oxygen as electron acceptor and generates super-
oxide anion and other reactive oxygen species as by-prod-
ucts in the process of uric acid degradation whereas xan-
thine dehydrogenase generates the reduced form of nic-
otinamide-adenine dinucleotide (Fig. 1). Both exogenous 
(present in fatty meat, organ meats, and seafood) and 
endogenous purines are major sources of uric acid in 
humans. Approximately two thirds of total body urate 
is produced endogenously while the remaining one third 
is originated from dietary purines.
The primary site of excretion of uric acid is the kidney. 
The normal urinary urate excretion is in the range of 
250 to 750 mg per day, approximately 70% of the daily 
urate production13). Although urate (the form of uric acid 
at blood pH of 7.4) is freely filtered in the glomerulus, 
there is evidence that both reabsorption and secretion 
occur in the proximal tubule, and as a consequence the 
fractional urate excretion is only 8% to 10% in the nor-
mal adult. Some adaptation occurs with renal disease, in 
which the fractional excretion of urate will increase to 
the 10% to 20%. The remainder of uric acid excretion 
occurs through the gut, where uric acid is degraded by 
uricolytic bacteria. Ideas of the handling of uric acid by 
the kidney have changed greatly over the past few deca-
des, with the identification, characterization, and iso-
lation of transporters and channels mainly or exclusively 
restricted to urate transport14,15).
The serum urate concentration reflects the balance be-
tween urate production and elimination. Hyperuricemia 
has been arbitrarily defined as >7.0 mg/dL in men and 
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>6.5 mg/dL in women. “Normal” serum uric acid levels 
in the population appear to be rising throughout the last 
century, likely as a consequence of changes in diet, and 
mean levels in men in the United States are now in the 
6.0 to 6.5 mg/dL range16). Hyperuricemia may also result 
from diets high in purines, from ethanol, and from fruc- 
tose. The effect of alcohol is in part related to increased 
urate synthesis, which is due to enhanced turnover of 
adenosine triphosphate (ATP) during the conversion of 
acetate to acetyl-CoA as part of the metabolism of etha-
nol17). In addition, acute alcohol consumption causes lac-
tate production, and because lactate is an antiuricosuric 
agent, it will reduce renal urate excretion and exacerbate 
hyperuricemia. Fructose (a simple sugar present in su-
crose, table sugar, high fructose corn syrup, honey, and 
fruits) can also induce a rapid rise in serum uric acid, 
due in part to its rapid phosphorylation in hepatocytes 
with the stimulation of adenosine monophosphate (AMP) 
deaminase and ATP consumption18). Chronic fructose 
consumption also stimulates uric acid synthesis. It has 
been proposed that the marked increase in fructose intake 
may have a role in the rising levels of serum uric acid 
and obesity worldwide19-20). Uric acid may also be af-
fected by exercise, with moderate exercise reducing urate 
levels (probably by increasing renal blood flow) and severe 
exercise causing a rise in uric acid (probably due to ATP 
consumption with adenosine and xanthine formation).
What happens first when cells are 
exposed to uric acid ?
One of the earliest phenomena observed in uric acid- 
exposed cells is the generation of oxidative stress21-26). 
Reactive oxygen species (ROS) is known to be associated 
with local inflammation, an impairment of nitric oxide 
(NO) generation, an activation of the renin-angiotensin 
system, insulin resistance and fat accumulation. Uric 
acid-induced ROS production seems paradoxical since 
uric acid has generally been considered to be one of the 
important anti-oxidants that protect the cardiovascular 
system from oxidative stress27,28). Uric acid prevents per-
oxynitrite-induced protein nitrosylation, lipid and pro-
tein peroxidation and an inactivation of tetrahydrobiop- 
terin, which results in scavenging free radical and chelat-
ing transitional metal ions. Consistent with an intrinsic 
anti-oxidant activity, uric acid administration in healthy 
volunteers and athletes reduced ROS production29). None- 
theless, many experimental and human studies demon-
strated the role of uric acid as pro-oxidants. Animals with 
hyperuricemia was reported to develop hypertension as-
sociated with an evidence for oxidative stress, and the 
hypertension was blocked by anti-oxidant treatment26).
Experimental studies demonstrated an activation of ox-
idative stress by uric acid in various cells.
1. Vascular endothelial and smooth muscle cells
Uric acid is already known to activate critical proin-
flammatory pathways and stimulate cell proliferation in 
vascular smooth muscle cells. In endothelial cells, uric 
acid decreases NO bioavailability and inhibits cell migra-
tion and proliferation, which are mediated in part by the 
expression of C-reactive protein and oxidative stress21,22). 
Uric acid significantly increased production of ROS begin-
ning at 5 min, and uric acid-induced senescence and apop-
tosis of human umbilical vein endothelial cells (HUVECs) 
were ameliorated by anti-oxidants, N-acetylcysteine or 
tempol. Uric acid also decreased mitochondrial deoxy-
ribonucleic acid (DNA) contents and intracellular ATP as-
sociated with ROS production in human aortic endothe-
lial cells30). Anti-oxidant, apocynin, blocked uric acid-in-
duced alteration in ROS generation and mitochondrial 
DNA content. Furthermore, the serum uric acid level cor-
related with the markers of oxidative stress in animal 
model of hyperuricemia30).
2. Renal tubular cells
In cultured renal tubular cells, uric acid induced epi-
thelial-to-mesenchymal transition (EMT) which was blo- 
cked by probenecid, an inhibitor of organic anion trans-
porter24). Anti-oxidants ameliorated uric acid-induced 
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EMT and apoptosis of renal tubules. N-acetylcysteine in-
hibited E-cadherin degradation and the expression of 
Snail24), suggesting EMT by uric acid was mediated by 
oxidative stress-driven inhibition of E-cadherin synthesis 
as well as E-cadherin degradation.
3. Adipocytes
Sautin et al. reported soluble uric acidper se stimulated 
an increase in NADPH oxidase activity and ROS pro-
duction in mature adipocytes as early as 30 minutes23). 
An interesting phenotype of these differentiated adipo-
cytes is a substantial uptake rate for uric acid with an 
expression of urate transporters (URAT1 and OAT4) and 
high basal level of ROS production. Uric acid stimulated 
NADPH oxidase-dependent ROS production, an activa-
tion of MAP kinases p38 and ERK 1/2, a decrease in 
NO bioavailability, and an increase in protein nitrosyla- 
tion and lipid oxidation. A recent study demonstrated 
uric acid-induced ROS production in adipocytes was 
mediated by an activation of the local renin-angiotensin 
system31).
Oxidative stress in the adipose tissue has recently been 
recognized as a major cause of insulin resistance and car-
diovascular disease32), and therefore hyperuricemia-in- 
duced alterations in oxidative homeostasis in the adipose 
tissue suggested the potential role of uric acid as a cause 
of insulin resistance.
4. Hepatocytes
We demonstrated uric acid-induced oxidative stress as 
a major mechanism of fat accumulation in cultured hep-
atocytes, HepG2 cells25). Uric acid (>6 mg/dL) increased 
H2O2 production and NOX activity in HepG2 cells from 
30 minutes, and antioxidants including diphenylene iodo-
nium and rotenone blocked uric acid-inducedtriglyceride 
accumulation, suggesting both NADPH oxidase-depend-
ent and mitochondria-mediated oxidative stress gen-
erated by uric acid were responsible for hepatic fat accu-
mulation33).
What are the lessons from 
epidemiologic studies ?
Many epidemiologic studies suggest that serum uric 
acid is at best a very weak predictor of cardiovascular 
disease after an adjustment of other risk factors in the 
general population34,35). This is mainly due to a strong 
correlation between serum uric acid level and other car-
diovascular risk factors including blood pressure, body 
mass index, creatinine, glucose, insulin, and lipid profiles. 
In contrast, uric acid appears to be a significant indepen- 
dent predictor of vascular and renal disease in hyper-
tensive patients and in subjects with high risk factors, 
such as diabetes, patients with chronic kidney disease or 
congestive heart failure36-39). This discrepancy regarding 
the effect of uric acid in relatively healthy populations 
and those in high-risk individuals raises two questions 
about clinical implication of hyperuricemia. First, if a cer-
tain factor is strongly related with other risk factors, it 
can never be interpreted as an independent risk factor 
by conventional statistics. Second, what is the molecular 
switch that convertsuric acid from anti-oxidant to pro- 
oxidant. It is particularly interesting since a mild elevation 
of uric acid, often observed in patients with uncomplicated 
obesity or hypertension, seems to impose no major effect 
on cardiovascular and renal complication34,35). It is neces-
sary to explore the molecular environment in which uric 
acid induces oxidative stress and an inflammatory reaction 
in hypertensive and/or diabetic subjects with high car-
diovascular risk factors.
Conclusion
Based upon the data from experimental and clinical 
research, uric acid seems to play a dual role as pro- and 
anti-oxidants. Interestingly, intracellular uric acid gen-
erally imposes the detrimental effects as a pro-oxidant 
in cultured cells and animal model of hyperuricemia, 
which is supported by the protective effects of an in-
hibitor of organic anion transporter via blocking the en-
try of uric acid into the cells and amelioration of oxida-
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tive stress. On the other hand, uric acid acts as anti-oxi-
dant only in the hydrophilic environment. The differ-
ential role of hyperuricemia in a healthy population and 
subjects with other risk factors for cardiovascular and 
metabolic disease suggests the presence of a molecular 
switch which controls the role of uric acid as anti-oxidant 
versus pro-oxidant. Regulation of this switch could be 
determined by the microenvironment in different com-
partment of human organism. Further studies will be nec-
essary to understand the Janus face of uric acid or yin 
and yang of hyperuricemia with a definition of molecular 
mechanism by which uric acid activates membranous and 
intracellular oxidative stress which is incompletely under- 
stood. Controlled clinical studies to investigate the effect 
of uric acid-lowering therapy while monitoring the mark-
ers of oxidative stress in subjects with different clinical 
characteristics, will provide valuable information regard-
ing the clinical implication of hyperuricemia.
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